Table I. Patient characteristics
Characteristic
Age (y), median (range)61 (40–80)
Male19 (76)
Stage (modified Rai)
 Early (0)0 (0)
 Intermediate (I, II)10 (40)
 Advanced (III, IV)15 (60)
FISH defects (hierarchical)a
 17p13 deletion1 (4)
 11q22 deletion2 (8)
 Trisomy 124 (16)
 None5 (20)
 13q14 deletion12 (48)
 Other1 (4)
IGHV somatic hypermutation (≥2%)
 Mutated10 (40)
 Unmutated15 (60)
ZAP70 expression (≥20%)
 Positive11 (44)
 Negative14 (56)
CD38 expression (≥30%)
 Positive7 (28)
 Negative18 (72)
Size of first OFA dose
 300 mg17 (68)
 <300 mgb8 (32)
Response to therapyc
 CR5 (25)
 CRi3 (12)
 Nodular partial response13 (52)
 Complete clinical response1 (4)
 Partial response1 (4)
 Stable/progressive disease2 (8)
  • Data are N (%) unless otherwise noted.

  • a Dohner classification (27).

  • b Dose administered: 100 mg (n = 1), 120 mg (n = 1), 150 mg (n = 4), 175 mg (n = 2).

  • c International Workshop on Chronic Lymphocytic Leukemia–modified National Cancer Institute criteria (25).

  • FISH, Fluorescence in situ hybridization; IGHV, Ig H chain V region.